Ruxolitinib Phosphate
Brand name: Jakafi
Rank #25 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$698.1M
Total Cost
46,655
Total Claims
$698.1M
Total Cost
1,856
Prescribers
$15K
Cost per Claim
1,657
Beneficiaries
47,298
30-Day Fills
$376K
Avg Cost/Provider
25
Avg Claims/Provider
Share of Medicare Part D Spending
0.25%
of total Medicare Part D spending
$698.1M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $698.1M total
🔎 Data Overview
Ranked #25 out of 500 drugs tracked by total cost. Ruxolitinib Phosphate represents a significant portion of Medicare drug spending.
At $14,962 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $376,112 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Average cost of $421,282 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Ruxolitinib Phosphate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Andrew Kuykendall | Internal Medicine | Tampa, FL | 387 | $7.1M |
| 2 | Christopher Benton | Medical Oncology | Englewood, CO | 305 | $5.3M |
| 3 | Maureen Thyne | Physician Assistant | New York, NY | 215 | $3.5M |
| 4 | Elizabeth Hexner | Hematology-Oncology | Philadelphia, PA | 197 | $3.3M |
| 5 | Kristen Kindervater | Physician Assistant | Ann Arbor, MI | 224 | $3.3M |
| 6 | Wahid Hanna | Hematology-Oncology | Knoxville, TN | 178 | $3.2M |
| 7 | Gabriela Hobbs | Hematology-Oncology | Boston, MA | 173 | $3.1M |
| 8 | Robin Cook | Nurse Practitioner | Houston, TX | 168 | $3.0M |
| 9 | Ghaith Abu Zeinah | Medical Oncology | New York, NY | 183 | $3.0M |
| 10 | John Winters | Hematology-Oncology | Scarborough, ME | 137 | $2.3M |
| 11 | Stephanie Tsai | Internal Medicine | Maywood, IL | 143 | $2.3M |
| 12 | Brady Stein | Hematology | Chicago, IL | 150 | $2.3M |
| 13 | Hannah Choe | Hematology | Columbus, OH | 131 | $2.2M |
| 14 | John Mascarenhas | Hematology | New York, NY | 120 | $2.2M |
| 15 | Sarah Wall | Hematology | Columbus, OH | 128 | $2.2M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 22 | Budesonide/Formoterol Fumarate (Symbicort) | $759.4M | 1,452,561 |
| 23 | Palbociclib (Ibrance) | $755.1M | 48,329 |
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology